ライフサイエンスコーパス: antiviral agent

1 ited for the development of a broad spectrum antiviral agent.

2 use of exogenous interferon as a therapeutic antiviral agent.

3 ibosomal protein L13a, whereby it acts as an antiviral agent.

4 n and thus holds promise as a broad-spectrum antiviral agent.

5 peptide has the potential to be a potential antiviral agent.

6 o increase the antiviral potency of this new antiviral agent.

7 suggests that it might also be useful as an antiviral agent.

8 N treated with oral valacyclovir as the sole antiviral agent.

9 unct to the immunosuppressive regimen and an antiviral agent.

10 s, resistant strains become dependent on the antiviral agent.

11 replication advantage in the presence of the antiviral agent.

12 or properties as a lead CaMKII inhibitor and antiviral agent.

13 essed prospectively in the era of new direct antiviral agents.

14 ave hampered the development of vaccines and antiviral agents.

15 lity in combination with other direct acting antiviral agents.

16 ormation for future clinical trials of newer antiviral agents.

17 all-oral regimen of 2 or more direct-acting antiviral agents.

18 to basic virology and the development of new antiviral agents.

19 ximum risk exposures and were given PEP with antiviral agents.

20 regimens of recently approved direct-acting antiviral agents.

21 velopment of MERS-CoV 3CL(pro) inhibitors as antiviral agents.

22 on therapies that contain only direct-acting antiviral agents.

23 NS2, to cyclosporine and other direct-acting antiviral agents.

24 vileged scaffold to obtain antibacterial and antiviral agents.

25 novel strategy for developing a new class of antiviral agents.

26 uch targets, which may foster development of antiviral agents.

27 of viral RNA replication, and evaluation of antiviral agents.

28 probing norovirus replication and evaluating antiviral agents.

29 ication and also for screening/evaluation of antiviral agents.

30 side-derived drugs, including anticancer and antiviral agents.

31 avirus infection, require development of new antiviral agents.

32 supplies of affordable pandemic vaccines and antiviral agents.

33 Thus, there is a need to discover novel antiviral agents.

34 ts for combining it with other direct-acting antiviral agents.

35 ive treatment with antibiotics and influenza antiviral agents.

36 nt recipients failing on currently available antiviral agents.

37 el CHC treatments that include direct-acting antiviral agents.

38 eptibility to first-generation direct-acting antiviral agents.

39 A/EMEA-approved gemcitabine represent potent antiviral agents.

40 useful for evaluating norovirus vaccines and antiviral agents.

41 despite the introduction of directly acting antiviral agents.

42 molecular clone has enabled discovery of new antiviral agents.

43 gy with broad implications for the design of antiviral agents.

44 a viable target for the development of novel antiviral agents.

45 d guidance to treat hospitalized adults with antiviral agents.

46 Tase becomes a rational target for designing antiviral agents.

47 ions for gene transfer or for development of antiviral agents.

48 of mTOR kinase inhibitors as broad-spectrum antiviral agents.

49 in the endosome may lead to novel classes of antiviral agents.

50 interactions is important for the design of antiviral agents.

51 nd those that differ in their sensitivity to antiviral agents.

52 mbers of an important class of antitumor and antiviral agents.

53 Viruses often evolve resistance to antiviral agents.

54 HIV-1 may become resistant to this class of antiviral agents.

55 s of clinical trials of some investigational antiviral agents.

56 ession is critical for designing therapeutic antiviral agents.

57 an attractive approach for the discovery of antiviral agents.

58 ly no approved treatments with direct-acting antiviral agents.

59 of protease inhibitors have been proposed as antiviral agents.

60 for which we have a very limited arsenal of antiviral agents.

61 ruses and may lead to the rational design of antiviral agents.

62 ed an all-oral regimen of >/=2 direct-acting antiviral agents.

63 ve CMV viraemia control without the need for antiviral agents.

64 novel insight into the utility of statins as antiviral agents.

65 iochemical relapse were re-treated with oral antiviral agents (11 during the first 18 months and 4 af

66 and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA) combination of simeprevir + TMC6

67 ia, were equally likely to receive influenza antiviral agents (78% vs 79%) but less likely to receive

68 brain penetration of the P-gp substrate and antiviral agent abacavir, in conjunction with a traceles

69 irs in the brain necessitates penetration of antiviral agents across the blood-brain barrier (BBB), a

70 de effects are rarely reported with the oral antiviral agents active against HBV.

71 trumental for designing carbohydrate-binding antiviral agents active against TBEV.

72 to investigate the association of individual antiviral agents (acyclovir, ganciclovir, and valgancicl

73 an be a potential candidate to be used as an antiviral agent against a broad range of influenza virus

74 has been recently identified as an effective antiviral agent against a number of pH-dependent viruses

75 e potential application of niclosamide as an antiviral agent against flavivirus infection and highlig

76 s also a cap-binding protein and is a potent antiviral agent against many plant, animal, and human vi

77 nt attractive targets for the development of antiviral agents against chronic HBV infection.

78 e use of modified nanoparticles as potential antiviral agents against diseases such as herpes simplex

79 In an effort toward discovery of novel antiviral agents against HBV, a group of benzamide (BA)

80 ors and warranted for further development as antiviral agents against HBV.IMPORTANCE HBV core protein

81 Antiviral agents against measles virus are not commercia

82 lymerase and will aid further development of antiviral agents against RSV.

83 refusion F-specific VHHs represent promising antiviral agents against RSV.

84 The combination of three direct-acting antiviral agents (AL-335, odalasvir, and simeprevir: JNJ

85 uld be cured by treatment with direct-acting antiviral agents alone in the absence of interferon.

86 ew classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted an

87 monstrate that favipiravir, a broad-spectrum antiviral agent and leading treatment option for influen

88 Daclatasvir is a direct-acting antiviral agent and potent inhibitor of NS5A, which is i

89 ROUND & AIMS: Daclatasvir is a direct-acting antiviral agent and potent inhibitor of NS5A, which is i

90 pe and addition of several new direct-acting antiviral agents and combination regimens into the thera

91 presume access to an array of direct acting antiviral agents and diagnostic tests that are not broad

92 o efforts aimed at developing broad-spectrum antiviral agents and help provide a more in-depth unders

93 ral immunity, a combination of direct-acting antiviral agents and immunotherapy are likely to be requ

94 Appropriate use of antiviral agents and improving influenza immunization co

95 is rapidly progressing toward generation of antiviral agents and increasingly effective vaccines.

96 h-risk patients to prioritize the use of new antiviral agents and intensive screening.

97 erties which augment the antiviral effect of antiviral agents and offer the potential to suppress the

98 he allosteric inhibitors of IN are promising antiviral agents and provide new information on their me

99 ed patients who received three direct-acting antiviral agents and ribavirin for 8 weeks and those who

100 evaluate multiple regimens of direct-acting antiviral agents and ribavirin in patients with HCV geno

101 titargeted therapy with the use of three new antiviral agents and ribavirin resulted in high rates of

102 In this phase 2b study, all-oral regimens of antiviral agents and ribavirin were effective both in pa

103 dies in both populations is the need for new antiviral agents and the necessity for combination thera

104 us, and the prospects for the development of antiviral agents and vaccines.

105 as well as to facilitate the development of antiviral agents and vaccines.

106 ould be applied to the future development of antiviral agents and vaccines.

107 replication cycles has led to many existing antiviral agents and will undoubtedly continue to be the

108 inclusion (with interferon then with direct antiviral agents) and underwent an ultrasound examinatio

109 gs and biocides, including antimicrobial and antiviral agents, anticancer drugs, photodynamic therapy

110 urrent therapies with all-oral direct-acting antiviral agents are associated with high rates of susta

111 gastroenteritis, yet no vaccines or specific antiviral agents are available.

112 Effective antiviral agents are difficult to develop because of the

113 Direct-acting antiviral agents are highly efficient treatment options

114 infection, for which diverse and multimodal antiviral agents are needed to prevent drug resistance.

115 Survival data with direct-acting antiviral agents are not available.

116 However, EBV-specific antiviral agents are not yet available.

117 Anticoagulation and antiviral agents are standard treatments for DIC but are

118 comes, with limited evidence that first-line antiviral agents are superior to lamivudine.

119 In the event of a pandemic, antiviral agents are the mainstay for treatment, but bro

120 ommunity to try drug repurposing of existing antiviral agents as a quick option against severe acute

121 It may prove useful as an antiviral agent, as a probe to study HCV replication, an

122 of this enzyme are potential broad-spectrum antiviral agents, as inhibition of this enzyme results i

123 SA is considered an attractive antitumor and antiviral agent because of its ability to selectively ex

124 infection, the addition of the direct-acting antiviral agent boceprevir to standard treatment with pe

125 Finally, we show that this new class of antiviral agents can overcome viral variants that confer

126 Antiviral agents can target viral or host gene products

127 n multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin.

128 enging pursuit, hallmarked by the paucity of antiviral agents currently prescribed.

129 There is a growing armamentarium of antiviral agents currently under development, although p

130 Voxilaprevir is a direct-acting antiviral agent (DAA) that targets the NS3/4A protease o

131 cellular carcinoma (HCC) after direct-acting antiviral agent (DAA) treatment.

132 irus (HCV) patients who fail directly-acting antiviral agent (DAA)-based treatment is unknown.

133 -drug interactions between HCV direct-acting antiviral agents (DAA) and HIV antiretrovirals.

134 who inject drugs (PWID), focusing on direct antiviral agents (DAA) and medication-assisted treatment

135 Direct acting antiviral agents (DAA) are highly effective yet expensiv

136 elp to improve the efficacy of direct-acting antiviral agents (DAA) in the treatment of HCV-infected

137 New direct-acting antiviral agents (DAA) offer an unprecedented opportunit

138 enal transplant population but direct acting antiviral agents (DAA) provide an effective cure of HCV

139 The effects of newer, directly acting antiviral agents (DAA) upon this risk are unknown.

140 Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV)

141 in development, including both direct-acting antiviral agents (DAAs) and host cofactor inhibitors.

142 Currently, direct-acting antiviral agents (DAAs) are evaluated in clinical trials

143 Direct-acting antiviral agents (DAAs) are highly effective and well to

144 Direct-acting antiviral agents (DAAs) are used increasingly to treat h

145 treatment with investigational direct-acting antiviral agents (DAAs) has not been extensively studied

146 ted surrogate outcome and that direct-acting antiviral agents (DAAs) have been demonstrated to improv

147 tment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options

148 virologic response (SVR) after direct acting antiviral agents (DAAs) holds promise for reducing hepat

149 n antiretroviral drugs and HCV direct-acting antiviral agents (DAAs) must be carefully considered.

150 Direct-acting antiviral agents (DAAs) represent the standard of care f

151 The new interferon-free direct antiviral agents (DAAs) showed high efficacy and safety,

152 rspective surveys the range of direct acting antiviral agents (DAAs) that target key steps in the vir

153 opments in directed use of new direct-acting antiviral agents (DAAs) to eliminate circulating HCV bef

154 eral new HCV therapies, called direct-acting antiviral agents (DAAs), are available that achieve cure

155 ree regimens that consist of directly acting antiviral agents (DAAs), which demonstrate improved effi

156 antially since the approval of direct-acting antiviral agents (DAAs).

157 ombination therapy consisting of only direct-antiviral agents (DAAs).

158 , which is the major target of direct-acting antiviral agents (DAAs).

159 ociated variants for all three direct-acting antiviral agents (DAAs); however, in all but 1 patient w

160 ')pA(3',5')p], c[G(3',5')pA(3',5')p] and the antiviral agent DMXAA, leading to similar "closed" confo

161 implications, suggesting that application of antiviral agents early in the disease course, even at a

162 luenza A viruses necessitates development of antiviral agents effective against various antigenic sub

163 splant with little expansion in the range of antiviral agents effective in treatment of CMV.

164 Six weeks prior to his consultation, antiviral agent entecavir was commenced for his chronic

165 e analogs representing an important class of antiviral agents, especially against positive-strand RNA

166 d strategy but with expanded distribution of antiviral agents (expanded prophylaxis strategy), and 3)

167 ta indicate that FIT-039 has potential as an antiviral agent for clinical therapeutics.

168 gest that TAT-Kalpha2 peptide is a potential antiviral agent for controlling emerging or re-emerging

169 dy raise the possibility of a broad spectrum antiviral agent for influenza virus and HPIVs.

170 tial for further development as an effective antiviral agent for treatment of HIV-1 infection.

171 To shorten the course of direct-acting antiviral agents for chronic hepatitis C virus (HCV) inf

172 iral therapy for HIV and preliminary data on antiviral agents for hepatitis C virus infection.

173 eptual platform to design nanoparticle-based antiviral agents for HIV-1 specifically and putatively f

174 These inhibitors are also effective antiviral agents for HIV-2-infected cells.

175 logs provides an approach for creating novel antiviral agents for IAV infections.

176 One promising target to identify new antiviral agents for norovirus is the viral polymerase,

177 as K04 may have potential as broad-spectrum antiviral agents for prevention and treatment of HCV inf

178 The use of available antiviral agents for the prevention of cytomegalovirus (

179 ently approved a number of new direct-acting antiviral agents for the treatment of chronic hepatitis

180 d for safe, effective, and readily available antiviral agents for treatment and prevention of acute E

181 ion, digoxin and digitoxin show potential as antiviral agents for treatment of serious adenovirus inf

182 s relatively resistant to the broad-spectrum antiviral agent foscarnet.

183 The availability of new directly acting antiviral agents has dramatically improved outcomes for

184 Five oral antiviral agents have been approved for the treatment of

185 spite its clinical significance, no specific antiviral agents have been approved for treatment of HMP

186 While highly efficacious directly-acting antiviral agents have been developed in recent years, th

187 Efforts to discover and develop poliovirus antiviral agents have been ongoing in earnest since the

188 Chemotherapy and antiviral agents have been used.

189 The CMV immunoglobulin (CMVIG) and antiviral agents have complementary modes of action.

190 Direct-acting antiviral agents have not been studied exclusively in pa

191 Ebola PEP, but newly developed experimental antiviral agents have potential advantages.

192 Second generation direct-acting antiviral agents have revolutionized therapy, with susta

193 line and estimating in vivo effectiveness of antiviral agents; however, it has not been used to chara

194 may be a therapeutic window in which use of antiviral agents (i.e., zidovudine and raltegravir) may

195 ay be considered a target for development of antiviral agents.IMPORTANCE Herpes simplex virus is a ma

196 s in designing studies to evaluate influenza antiviral agents in a hospitalized setting.

197 New evidence on the safety of antiviral agents in children and studies on intervention

198 The efficacy of directly acting antiviral agents in interferon-free regimens for the tre

199 Clinical trials of direct-acting antiviral agents in patients chronically infected with h

200 he duration of prophylaxis or treatment with antiviral agents in those who have achieved CMV-specific

201 to sensitize EBV(+) human lymphoma cells to antiviral agents in vitro.

202 ze how QL47, a host-targeted, small-molecule antiviral agent, inhibits steady-state viral protein exp

203 on of several promising therapies, including antiviral agents, interleukin-6 inhibitors, and convales

204 require an adaptive mechanism to convert the antiviral agent into a beneficial growth factor.

205 primary virological end points in studies of antiviral agents involving patients who are hospitalized

206 ombination of SOF and a second direct-acting antiviral agent is highly effective in TN patients with

207 A safe broad-spectrum antiviral agent is needed to treat this unmet medical ne

208 revention of virus disease by vaccination or antiviral agents is difficult to achieve.

209 nucleoside and non-nucleoside inhibitors as antiviral agents is discussed with particular emphasis o

210 C virus (HCV) genotype 1 with direct-acting antiviral agents is often accompanied by the emergence o

211 lternatives to annual influenza vaccines and antiviral agents licensed for mitigating influenza infec

212 Antiviral agents may also have a potential role in the m

213 , including blockade of multiple pathways or antiviral agents, need to be sought for this high unmet

214 Entecavir is a potent oral antiviral agent of high genetic barrier for the treatmen

215 tment (using boceprevir as the direct-acting antiviral agent) of those with chronic HCV infection cos

216 The impact of the individual antiviral agent on long-term outcome was further evaluat

217 ponse can be achieved with two direct-acting antiviral agents only.

218 ll-type-specific effects upon treatment with antiviral agents, opening additional avenues of research

219 n in the recipient can be prevented by using antiviral agents or by boosting protective anti-HBs tite

220 r control: Treating symptomatic persons with antiviral agents or encouraging home isolation would be

221 selected and characterized as candidates for antiviral agents or reagents for standardization of vacc

222 on when administered in combination with the antiviral agent oseltamivir.

223 e presence of neutralizing antibodies and an antiviral agent, Oseltamivir, influenza virus can exploi

224 eeks of SOF along with another direct-acting antiviral agent plus RBV achieved SVR12-9 of 9 (100%) of

225 While antiviral agents provide effective prophylaxis, there ar

226 d facilitate the discovery of a new class of antiviral agents providing HIV-1 patients with broader t

227 NS3/4A protease inhibitor) are direct-acting antiviral agents recently approved in the United States

228 NS3/4A protease inhibitor) are direct-acting antiviral agents recently approved in the United States

229 With the availability of direct-acting antiviral agents, recently approved therapies and those

230 r evaluation of the three-drug direct-acting antiviral agent regimen of grazoprevir 100 mg plus ruzas

231 Regulatory small RNAs are well known as antiviral agents, regulators of gene expression, and def

232 onal antibody ZMapp (the control group), the antiviral agent remdesivir, the single monoclonal antibo

233 engla viruses and is the first submicromolar antiviral agent reported for some of these strains, ther

234 Many other direct-acting antiviral agents representing several classes, as well a

235 HIV-1 replication in the presence of antiviral agents results in evolution of drug-resistant

236 L and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properti

237 n to a similar extent as the clinically used antiviral agent, ribavirin.

238 Moreover, treatment with cidofovir, a potent antiviral agent, robustly inhibits the sT-mediated enhan

239 ieve its potential as a broad-spectrum human antiviral agent should be explored.

240 Two new oral antiviral agents, simeprevir and sofosbuvir, have alread

241 BMS-791325 is a novel direct antiviral agent specifically targeting HCV NS5B, an RNA-

242 able (ribavirin) or investigational (DAS181) antiviral agents still needs to be determined.

243 Direct-acting antiviral agents suppress hepatitis B virus (HBV) load,

244 Antiviral agents suppress hepatitis B virus (HBV) replic

245 Tofacitinib, as well as antiviral agents, suppressed culprit-induced T cell prol

246 the most promising approaches, including new antiviral agents, symptomatic or immunomodulatory drugs,

247 and show promise for further development of antiviral agents targeting highly resistant PR mutants.

248 ng the possibility to develop broad-spectrum antiviral agents targeting host factors.

249 ognition with PRNTase but also for designing antiviral agents targeting this enzyme.

250 (HCV), the combination of the direct-acting antiviral agent telaprevir, pegylated-interferon alfa (P

251 Additionally, IFN-lambda is a potent antiviral agent that has certain advantages for clinical

252 Remdesivir (RDV) is a direct-acting antiviral agent that is used to treat patients with seve

253 mong all family members, which suggests that antiviral agents that block these steps might be effecti

254 The development of direct-acting antiviral agents that can cure a chronic hepatitis C vir

255 ighlight a desperate need for broad-spectrum antiviral agents that can effectively control infections

256 Owing to the wide availability of antiviral agents that effectively suppress HBV replicati

257 yanobacterial lectin, exemplifies a class of antiviral agents that inhibit HIV by binding to the high

258 nofovir disoproxil fumarate (TDF) are potent antiviral agents that might have additive or synergistic

259 Currently there are no approved antiviral agents that reduce or eliminate HPV and revers

260 sistant phenotypes that could be selected by antiviral agents that specifically target capsid assembl

261 uidelines for developing new N protein-based antiviral agents that target CoVs.

262 ysiological conditions and identification of antiviral agents that target HBc.

263 s are potentiated in combination with direct antiviral agents that target HBV-DNA polymerase.

264 the activity of a broad and potent class of antiviral agents that target mannose sugars on the envel

265 It is a challenge to develop direct-acting antiviral agents that target the nonstructural protein 3

266 Antiviral agents that target this novel aspect of GPC me

267 ing drug-drug interactions for direct-acting antiviral agents, the interactions being the most clinic

268 Before the advent of effective antiviral agents, the primary treatment was reduction in

269 Resumption of direct-acting antiviral agent therapy after a temporary interruption a

270 ased dual, triple, or all-oral direct acting antiviral agent therapy, respectively, whereas 79% of pa

271 With the advent of direct-acting antiviral agents, there has been a rapid rise in hepatit

272 n and the potential use of 25HC as a natural antiviral agent to combat ZIKV infection and prevent ZIK

273 lving a mechanism to productively utilize an antiviral agent to stimulate its fitness above the uninh

274 No licensed antiviral agent to treat DENV infections is currently av

275 on and, hence, can be targeted for designing antiviral agents to block KSHV virion production.IMPORTA

276 We focused on those treated with antiviral agents to explore the effect of early treatmen

277 l molecular targets for development of novel antiviral agents to improve the therapeutic efficacy of

278 from the addition of multiple direct-acting antiviral agents to their treatment regimen.

279 The development of direct-acting antiviral agents to treat HCV has focused predominantly

280 The advent of direct-acting antiviral agents to treat hepatitis C virus (HCV) infect

281 er development of BDAA or its derivatives as antiviral agents to treat yellow fever.

282 Despite the availability of new antiviral agents, treatment remains suboptimal.

283 Prophylaxis for CMV using antiviral agents (typically oral valganciclovir or intra

284 (NNRTIs) are potent and commonly prescribed antiviral agents used in combination therapy (CART) of h

285 Sensitivity to antiviral agents was evaluated.

286 PEP with antiviral agents was given to health-care workers assess

287 Treatment with antiviral agents was the only independent protective fac

288 grase stimulator (IS) compounds as potential antiviral agents, we have developed a nonradioactive ass

289 been treated previously with a direct-acting antiviral agent were assigned randomly to groups given s

290 RECENT FINDINGS: Two new directly acting antiviral agents were approved in 2011 for use in hepati

291 onse was achieved when the two direct-acting antiviral agents were combined with peginterferon alfa-2

292 ng therapy, and resistance mutations to both antiviral agents were found in all cases; 1 patient had

293 try who started treatment with direct-acting antiviral agents while awaiting LT were identified retro

294 Other antiviral agents will be available during 2014.

295 Entecavir is a potent antiviral agent with a low rate of drug resistance in nu

296 There are no FDA-licensed vaccines or antiviral agents with activity against RVFV, and details

297 substituent provided a number of more potent antiviral agents with IC(50) values ranging to 2.5 muM.

298 and monitoring of herpesvirus infections and antiviral agents with improved efficacy in prophylaxis a

299 ed patients who received three direct-acting antiviral agents (with the ABT-450/r dose administered a

300 ents (78% vs 79%) but less likely to receive antiviral agents within </=2 days of illness onset (28%